GlaxoSmithKline PLC (GSK): Price and Financial Metrics

GlaxoSmithKline PLC (GSK)

Today's Latest Price: $37.89 USD

0.29 (0.77%)

Updated Mar 31 8:04pm

Add GSK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

GSK Stock Summary

  • GSK has a higher market value than 98.53% of US stocks; more precisely, its current market capitalization is $91,512,737,927.
  • Glaxosmithkline Plc's stock had its IPO on July 9, 1986, making it an older stock than 92.17% of US equities in our set.
  • The volatility of Glaxosmithkline Plc's share price is greater than that of just 6.78% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Glaxosmithkline Plc, a group of peers worth examining would be IBM, SNY, AZN, DHR, and UTX.
  • Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to
GSK Daily Price Range
GSK 52-Week Price Range

GSK Stock Price Chart More Charts

GSK Price/Volume Stats

Current price $37.89 52-week high $48.25
Prev. close $37.60 52-week low $31.43
Day low $37.34 Volume 5,204,600
Day high $38.42 Avg. volume 4,949,515
50-day MA $41.66 Dividend yield 6.3%
200-day MA $42.65 Market Cap 94.55B

GlaxoSmithKline PLC (GSK) Company Bio

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company’s wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.

GSK Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Glaxosmithkline Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Glaxosmithkline Plc ranked in the 30th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 33.17%. As for the metrics that stood out in our discounted cash flow analysis of Glaxosmithkline Plc, consider:

  • 83% of the company's capital comes from equity, which is greater than 69.41% of stocks in our cash flow based forecasting set.
  • The weighted average cost of capital for the company is 7. This value is greater than only 19.91% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Glaxosmithkline Plc? See HBIO, HRC, JNJ, CHE, and LHCG.

GSK Latest News Stream

Event/TimeNews Detail
Loading, please wait...

GSK Latest Social Stream

Loading social stream, please wait...

View Full GSK Social Stream

GSK Price Returns

1-mo -10.95%
3-mo -18.13%
6-mo -7.50%
1-year -5.08%
3-year 4.84%
5-year 3.50%
YTD -18.25%
2019 29.12%
2018 13.70%
2017 -3.03%
2016 -1.10%
2015 -0.27%

GSK Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full GSK Dividend History

Continue Researching GSK

Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:

Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8819 seconds.